Latest Headlines
-
Abzena Launches EpiScreen® 2.0 Immunogenicity Platform
4/25/2024
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics.
-
AGC Biologics Selects Cytiva To Provide FlexFactory Platforms In New Biomanufacturing Facility In Japan
4/25/2024
AGC Biologics, in collaboration with Cytiva, is set to innovate its production line at its new facility in Yokohama, Japan with two FlexFactory manufacturing platforms.
-
Successful Production Of Cancer-Specific Therapeutic Antibody Fragments
4/23/2024
AGC Biologics announced the completion of work with VAR2 Pharmaceuticals on the production of the company’s two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment.
-
Biotech Company Uses Microbial Fermentation Process In Carbon Recycling Technology
4/17/2024
“We want it so every child in the world can pick up a crayon and color the sky and have that crayon that they pick is blue, right, and today that’s not the reality for every kid around the world,” Zara Summers, Chief Science Officer at LanzaTech, a Biotech Company, vividly articulates the company’s goal to reduce fossil fuel consumption and instead, recycle carbon, that is already above ground to create necessities.
-
AES Clean Technology Sets New Standards For Cleanliness And Efficiency In cleanrooms with The Launch Of Its CleanLock Module
4/16/2024
AES Clean Technology, a leading provider of high-performance cleanroom facilities, has launched its CleanLock Module™ today. This revolutionary airlock solution enhances cleanliness, speed, and efficiency in cleanroom project execution.
-
Imugene And Kincell Bio Announce Strategic Manufacturing And Process Development Partnership
4/16/2024
Imugene, Ltd. (“Imugene”)(ASX: IMU) and Kincell Bio, LLC (“Kincell”), announce a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina Current Good Manufacturing Practice (CGMP) manufacturing facility and the transfer of process and analytical development activities to Kincell.
-
John Witkowski Appointed President & CEO Of Solesis
4/9/2024
Solesis, a leader in the custom design, development, and manufacturing of textile- and polymer-based healthcare solutions for the medical device and biopharmaceutical industries, is pleased to announce that John Witkowski has been appointed as the new President & CEO, effective immediately. In this role, Witkowski is responsible for developing the strategic priorities for Solesis and executing world-class business operations to support customers and drive long-term, sustainable growth.
-
Ingersoll Rand to Acquire ILC Dover to Expand Presence in Life Sciences
3/25/2024
Ingersoll Rand Inc. (NYSE:IR), a global provider of mission-critical flow creation and industrial solutions, has entered into an agreement to acquire ILC Dover (“ILC”) from New Mountain Capital, LLC, a leading growth-oriented investment firm with approximately $50 billion in assets under management. The deal includes an upfront cash purchase price of approximately $2.325 billion and an earnout tied to the achievement of select operating efficiency metrics in 2024. At its maximum payout, the earnout
-
Honeywell Announces Upcoming Webinar and Conference Schedule
3/19/2024
Visit us at Booth 17 to learn more about our unified manufacturing operations platform and how it accelerates innovation and increases efficiency, quality, and compliance.
-
Pluri Selected As CDMO By Remedy Cell For Cell-Derived Cell-Free Drug Manufacturing
3/14/2024
Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today announced that its CDMO division (PluriCDMO™) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.